SAN FRANCISCO, August 06, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials in the Company’s registrational ...

All three trials in the Company’s registrational ECLIPSE program for chronic hepatitis delta (CHD) have now been initiated.

The English Department offers concentrations and certificates in multiple kinds of writing, from creative writing to science writing, and from technical writing to journalism.

ECLIPSE is a registrational program to evaluate the safety and efficacy of tobevibart in combination with elebsiran in patients with chronic hepatitis delta (CHD).

The English Department offers graduate and undergraduate certificates in creative writing.  The undergraduate program is workshop-based, offering a supportive environment with peers and ...

GPT-5, OpenAI's latest release, will decide for you which model is best for certain tasks. Here's the difference between them.